Tesaglitazar
-
Tesaglitazar
structure -
-
CAS No:
251565-85-2
-
Formula:
C20H24O7S
-
Chemical Name:
Tesaglitazar
-
Synonyms:
Benzenepropanoic acid,α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]-,(αS)-;(αS)-α-Ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]benzenepropanoic acid;AZ 242;Tesaglitazar;AR-H 039242;Galida;AR-H 039242XX;(S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid;Tesaglitizar;(S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid;(2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
-
CAS No:
Description
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.|Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Tesaglitazar is more potent on the gamma subtype than on the alpha subtype of PPAR. This agent improves atherogenic dyslipidemia but may cause an increase in fibrosarcoma formation.
Safety Information
|Warning|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Information
Investigated for use/treatment in diabetes mellitus type 2.
Treatment with tesaglitazar lowered fasting plasma glucose, improved glucose tolerance, substantially reduced fasting and postload insulin levels, and markedly lowered fasting TG and improved lipid tolerance.
(S)-2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid
Tesaglitazar Use and Manufacturing
Dual -acting peroxisome proliferator-activated receptor (PPAR) α and γ agonist. Antidiabetic.
Computed Properties
Molecular Weight:408.5
XLogP3:3.5
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:11
Exact Mass:408.12427427
Monoisotopic Mass:408.12427427
Topological Polar Surface Area:108
Heavy Atom Count:28
Complexity:556
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
